13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q2 2023. See the latest, Q2 2026 →
Reported value
$1.86B
+3.2% on the quarter before
Positions
47
1 new · 3 sold out
Top 10
84.0%
of the value
Est. gain
+$157.3M
on stocks held all quarter
Est. return
+9.5%
on those stocks since Q1 2023
Positions as of Jun 30, 2023, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2023. Striped tiles are options.
Largest buys
Since Q1 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Gitlab Inc.~$36.5MAdded · 3.7% → 7.3%+713,578 shares
- CrowdStrike~$17.6MAdded · 8.9% → 10.1%+120,145 shares
- Evelo Biosciences Inc.~$172,328New · 0.0% → 0.0%+53,024 shares
Largest sells
Since Q1 2023, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Duolingo Inc.~$74.7MSold out · 4.1% → 0.0%−523,824 shares
- Robinhood~$43.1MCut · 2.7% → 0.3%−4,316,321 shares
- Prime Medicine, Inc.~$20.8MCut · 9.1% → 9.3%−1,422,190 shares
- 23andme Holding Co.~$15.4MSold out · 0.9% → 0.0%−6,736,785 shares
- Dexcom Inc~$4.8MCut · 8.1% → 8.4%−37,194 shares
- Evelo Biosciences Inc.~$190,889Sold out · 0.0% → 0.0%−1,060,495 shares
Holdings
As of Jun 30, 2023. Changes are in shares against Mar 31, 2023, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| UiPathCL A · shares 0% · price −5.6% | 12.5% | $233.1M | −$13.9M | ||||||||
| Verve Therapeutics IncCOM · shares 0% · price +30.0% | 10.6% | $197.8M | +$45.7M | ||||||||
| Oscar Health Inc.CL A · shares 0% · price +23.2% | 10.4% | $193.8M | +$36.5M | ||||||||
| CrowdStrikeCL A · shares +10% · price +7.0% | 10.1% | $188.5M | +$11.2M | ||||||||
| Prime Medicine, Inc.COM · shares −11% · price +19.1% | 9.3% | $173.8M | +$27.9M | ||||||||
| Dexcom IncCOM · shares −3.0% · price +10.6% | 8.4% | $155.9M | +$15.0M | ||||||||
| Gitlab Inc.CLASS A COM · shares +37% · price +49.1% | 7.3% | $135.3M | +$32.5M | ||||||||
| Planet Labs Inc.COM CL A · shares 0% · price −18.1% | 5.5% | $102.9M | −$22.7M | ||||||||
| SnowflakeCL A · shares 0% · price +14.1% | 5.1% | $94.3M | +$11.6M | ||||||||
| Eqrx Inc.COM · shares 0% · price −4.1% | 4.8% | $88.7M | −$3.8M | ||||||||
| Freshworks IncCLASS A COM · shares 0% · price +14.5% | 3.8% | $70.9M | +$9.0M | ||||||||
| Lyft IncCL A COM · shares 0% · price +3.5% | 1.9% | $35.5M | +$1.2M | ||||||||
| Benson Hill Inc.COMMON STOCK · shares 0% · price +13.0% | 1.1% | $20.0M | +$2.3M | ||||||||
| Relay Therapeutics Inc.COM · shares 0% · price −23.7% | 1.1% | $19.7M | −$6.1M | ||||||||
| Desktop Metal Inc.COM CL A · shares 0% · price −23.0% | 1.1% | $19.6M | −$5.9M | ||||||||
| Lyell Immunopharma Inc.COM · shares 0% · price +34.7% | 1.0% | $18.7M | +$4.8M | ||||||||
| Sana Biotechnology Inc.COM · shares 0% · price +82.3% | 0.90% | $16.8M | +$7.6M | ||||||||
| Beam Therapeutics Inc.COM · shares 0% · price +4.3% | 0.55% | $10.3M | +$421,301 | ||||||||
| Rapt Therapeutics Inc.COM · shares 0% · price +1.9% | 0.54% | $10.1M | +$189,094 | ||||||||
| Monte Rosa Therapeutics Inc.COM · shares 0% · price −12.1% | 0.54% | $10.0M | −$1.4M | ||||||||
| Illumina Inc.COM · shares 0% · price −19.4% | 0.54% | $10.0M | −$2.4M | ||||||||
| Decibel Therapeutics Inc.COM · shares 0% · price +27.5% | 0.34% | $6.3M | +$1.4M | ||||||||
| RobinhoodCOM CL A · shares −88% · price +2.8% | 0.33% | $6.1M | +$165,298 | ||||||||
| Invivyd Inc.COM · shares 0% · price −12.5% | 0.32% | $6.0M | −$852,118 | ||||||||
| Tenaya Therapeutics Inc.COM · shares 0% · price +106.0% | 0.29% | $5.4M | +$2.8M | ||||||||
| Total · 47 positions | 100% | $1.86B | +$157.3M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q1 2023 to Q2 2023: 46 stocks held throughout, up $157.3M (+9.5%).
- Verve Therapeutics Inc+$45.7M+30%
- Oscar Health Inc.+$36.5M+23%
- Gitlab Inc.+$32.5M+49%
- Prime Medicine, Inc.+$27.9M+19%
- Dexcom Inc+$15.0M+11%
- Eqrx Inc.−$3.8M−4%
- Desktop Metal Inc.−$5.9M−23%
- Relay Therapeutics Inc.−$6.1M−24%
- UiPath−$13.9M−6%
- Planet Labs Inc.−$22.7M−18%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |